SC

Staar Surgical Company

STAA
NASDAQHealth Care
$28.37
USD
-0.53(-1.83%)
At close: Jun 12, 20:00 UTC

Open

$28.30

Prev. Close

$28.33

High

$28.40

Low

$28.26

Market Snapshot

Market Cap

$1.4B

P/E Ratio

-66.8

EPS

-0.42

Revenue

$313.9M

Employees

921

Why STAA moved

Staar Surgical Company reported a remarkable 120% revenue increase in Q1, prompting discussions about the sustainability of such rapid growth in the ophthalmic industry.

About

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Recently from Cashu